Business

Biopharma’s Huge Week Is Upon Us

Biopharma’s Big Week Is Upon Us


That is the online model of Brainstorm Well being Every day, Fortune’s every day publication on the highest well being care information. To get it delivered every day to your in-box, join right here.

Hey and comfortable Monday, readers—I hope you had a beautiful weekend.

Right here we go once more. It’s that week in San Francisco. The massive biopharma bash. The lifetime of the life sciences scene. The Woodstock of would-be drug builders.

I’m talking, in fact, concerning the 38th annual JP Morgan Healthcare Convention—a confab that pulls hundreds of buyers, biopharma executives, lecturers, and a good variety of us ink-stained wretches desirous to cowl the craziness annually.

I gained’t be attending the festivities, aka #JPM20, in individual this time round. However that doesn’t imply we gained’t have loads of updates, interviews, and key insights from what performs out over the next week within the Bay (the truth is, look to this column for some breaking information a few main genomic sequencing participant tomorrow).

And there’s already been a couple of notable developments to set off the convention and all of the wheeling-and-dealing that comes with it. As an example: Med tech big Medtronic introduced that it’s buying Stimgenics, an organization centered on spinal wire stimulation so as to deal with persistent ache simply forward of JPM week; Illumina, a titan of the genomics house, reached a partnership with Swiss drug developer Roche to bolster the latter’s diagnostics enterprise; and digital physician go to specialist Teladoc introduced it could purchase rival InTouch Well being in a $600 million deal that features $150 million in upfront money.

A lot, way more to return. Within the meantime, learn on for the day’s information.

Sy Mukherjee
sayak.mukherjee@fortune.com
@the_sy_guy